Drugs in Dev.
Infections and Infectious Diseases
Discovery
Germany 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : US Department of Defense
Deal Size : $74.0 million
Deal Type : Agreement
Details : Under the agreement, Evotec Biologics will develop drug product prototypes of new monoclonal antibodies (mAbs) using AI-driven de novo antibody design through the execution of Phase I first-in human clinical trials.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : US Department of Defense
Deal Size : $74.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Open Philanthropy
Deal Size : $1.7 million
Deal Type : Funding
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Details : The funding will support the discovery and development of RNA-targeting small molecules by leveraging its rSM platform for potential first-in-class therapeutics against Henipaviruses.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Open Philanthropy
Deal Size : $1.7 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $6.6 million
Deal Type : Funding
Evotec Receives US$ 6.6 m Grant for Drug Discovery in Tuberculosis
Details : The funding will support TB drug discovery, and will allow the Company to progress a portfolio of TB drug discovery projects that have the potential to contribute to a universal, shorter, safer and simpler TB drug regimen.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 24, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $6.6 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Evotec Biologics Receives Grant to Enable an Antibody Product for the Prevention of COVID-19
Details : Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the wor...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 19, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Sun Yat-sen University
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under this agreement, Secarna will employ its proprietary LNAplusTM platform to develop antisense oligonucleotides (ASOs) which specifically suppress the expression of a certain host factor that is essential for the viral infection cycle.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 28, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Sun Yat-sen University
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NI007
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Neurimmune
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration agreement, Neurimmune and Ethris will jointly conduct research and development activities while sharing costs and revenues resulting from the collaboration.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
April 01, 2020
Lead Product(s) : NI007
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Neurimmune
Deal Size : Undisclosed
Deal Type : Collaboration
